Related Experiment Video
Updated: Jun 7, 2026
Determination of the Procoagulant Activity of Extracellular Vesicle (EV) Using EV-Activated Clotting Time (EV-ACT)
Published on: August 4, 2023
Role of microparticles in the hemostatic dysfunction in acute promyelocytic leukemia
Hau C Kwaan1, Eduardo Magalhães Rego
1Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, Illinois 60611, USA. h-kwaan@northwestern.edu
Abstract:
Serious bleeding and thrombotic complications are frequent in acute promyelocytic leukemia (APL) and are major causes of morbidity and mortality. Microparticles (MP) have been used to study the risk and pathogenesis of thrombosis in many malignant disorders. To date, from published articles, this approach had not been applied to APL. In this article, the hemostatic dysfunction in this disorder is briefly reviewed. A study design to address this problem using MP is described. MP bearing tissue factor, profibrinolytic factors (tissue plasminogen activator and annexin A2), and the antifibrinolytic factor plasminogen activator inhibitor type 1 were measured using flow cytometry. The cellular origin of the MP was identified by specific cell surface markers. Comparison of the various populations of MP was made between samples collected at the time of diagnosis with those collected at molecular remission. Preliminary data suggest that this approach is feasible.
Insights
Serious bleeding and clotting issues are common in acute promyelocytic leukemia (APL). This study explores using microparticles (MP) to understand thrombosis risk and hemostatic dysfunction in APL patients.
Area of Science:
- Hematology
- Oncology
- Thrombosis Research
Background:
- Acute promyelocytic leukemia (APL) is associated with severe bleeding and thrombotic complications, leading to significant morbidity and mortality.
- Microparticles (MP) are recognized biomarkers for thrombosis risk in various cancers, but their role in APL pathogenesis remains understudied.
Purpose of the Study:
- To investigate the hemostatic dysfunction in APL by analyzing circulating microparticles (MP).
- To establish a feasible study design for evaluating MP in APL patients at diagnosis and remission.
Main Methods:
- Utilized flow cytometry to quantify MP expressing tissue factor, profibrinolytic factors (tissue plasminogen activator, annexin A2), and antifibrinolytic factors (plasminogen activator inhibitor type 1).
- Identified the cellular origin of MP using specific cell surface markers.
- Compared MP populations between APL patients at diagnosis and those in molecular remission.
Main Results:
- Developed and described a study design for MP analysis in APL.
- Preliminary data indicate the feasibility of using MP analysis to assess hemostatic dysfunction in APL.
Conclusions:
- Microparticle analysis presents a feasible approach to investigate the complex hemostatic dysfunction in acute promyelocytic leukemia.
- Further research using this methodology can elucidate the role of MP in APL-associated thrombosis and bleeding.
Related Concept Videos
01:18Structure and Function of Platelets
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000 platelets, with...
01:01Regulation of Hematopoietic Stem Cells
01:15Differentiation of Common Myeloid Progenitor Cells
01:28Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...